Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms

Clinical Immunology

Volumn 141, Issue 1, 2011, Pages 36-48

  Mu, Lili ^a   Zhang, Yao ^a   Sun, Bo ^a   Wang, Jinghua ^a   Xie, Xiaoli ^a   Li, Na ^a   Zhang, Jia ^a   Kong, Qingfei ^a   Liu, Yumei ^a   Han, Zhijuan ^a   Wang, Guangyou ^a   Fu, Zheng ^b   Yu, Bo ^a,c   Li, Guozhong ^d   Li, Hulun ^a,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; Experimental autoimmune myasthenia gravis; Myasthenia gravis; RAGE; S100B

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLOOXYGENASE 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROTEIN S100B; RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVITY; CELL PROLIFERATION; CELL SECRETION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HYPOTHESIS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION;

ANIMALS; AUTOANTIBODIES; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; LIGANDS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; MYELIN BASIC PROTEINS; NERVE GROWTH FACTORS; NITROBENZENES; PEPTIDE FRAGMENTS; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS; SULFONAMIDES; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 80053131033     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.04.013     Document Type: Article

References (35)

1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2002, 2:797-804.
2. Lennon V.A., Lindstrom J.M., Seybold M.E. Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 1975, 141:1365-1375.
3. De Baets M., Stassen M., Losen M., Zhang X., Machiels B. Immunoregulation in experimental autoimmune myasthenia gravis - about T cells, antibodies, and endplates. Ann. N.Y. Acad. Sci. 2003, 998:308-317.
4. Wang W., Milani M., Ostlie N., Okita D., Agarwal R.K., Caspi R.R., Conti-Fine B.M. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J. Immunol. 2007, 178:7072-7080.
5. Mu L., Sun B., Kong Q., Wang J., Wang G., Zhang S., Wang D., Liu Y., An H., Li H. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 2009, 128:e826-e836.
6. Drinda S., Franke S., Ruster M., Petrow P., Pullig O., Stein G., Hein G. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol. Int. 2005, 25:411-413.
7. Valencia J.V., Mone M., Zhang J., Weetall M., Buxton F.P., Hughes T.E. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes 2004, 53:743-751.
8. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
9. Yan S.S., Wu Z.Y., Zhang H.P., Furtado G., Chen X., Yan S.F., Schmidt A.M., Brown C., Stern A., LaFaille J., Chess L., Stern D.M., Jiang H. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat. Med. 2003, 9:287-293.
10. Chen Y., Yan S.S., Colgan J., Zhang H.P., Luban J., Schmidt A.M., Stern D., Herold K.C. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J. Immunol. 2004, 173:1399-1405.
11. Shanmugam N., Kim Y.S., Lanting L., Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem. 2003, 278:34834-34844.
12. Bianchi R., Giambanco I., Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol. Aging 2010, 31:665-677.
13. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., Yan S.D. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 2001, 171:29-45.
14. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
15. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108:949-955.
16. Wendt T., Bucciarelli L., Qu W., Lu Y., Yan S.F., Stern D.M., Schmidt A.M. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr. Atheroscler. Rep. 2002, 4:228-237.
17. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
18. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 2000, 1498:99-111.
19. Iikuni N., Lourenco E.V., Hahn B.H., La Cava A. Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. J. Immunol. 2009, 183:1518-1522.
20. Matsuzaki J., Tsuji T., Imazeki I., Ikeda H., Nishimura T. Immunosteroid as a regulator for Th1/Th2 balance: its possible role in autoimmune diseases. Autoimmunity 2005, 38:369-375.
21. Keino H., Takeuchi M., Usui Y., Hattori T., Yamakawa N., Kezuka T., Sakai J.I., Usui M. Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis. Br. J. Ophthalmol. 2007, 91:105-110.
22. Nielsen C.H., Hegedus L., Rieneck K., Moeller A.C., Leslie R.G., Bendtzen K. Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease. Clin. Exp. Immunol. 2007, 147:287-295.
23. Crane I.J., Forrester J.V. Th1 and Th2 lymphocytes in autoimmune disease. Crit. Rev. Immunol. 2005, 25:75-102.
24. Milani M., Ostlie N., Wu H., Wang W., Conti-Fine B.M. CD4+ T and B cells cooperate in the immunoregulation of Experimental Autoimmune Myasthenia Gravis. J. Neuroimmunol. 2006, 179:152-162.
25. Zhu J., Paul W.E. CD4 T cells: fates, functions, and faults. Blood 2008, 112:1557-1569.
26. Deng C., Goluszko E., Tuzun E., Yang H., Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 2002, 169:1077-1083.
27. Goluszko E., Deng C., Poussin M.A., Christadoss P. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J. Neuroimmunol. 2002, 122:85-93.
28. Gu D., Wogensen L., Calcutt N.A., Xia C., Zhu S., Merlie J.P., Fox H.S., Lindstrom J., Powell H.C., Sarvetnick N. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J. Exp. Med. 1995, 181:547-557.
29. Wang H.B., Shi F.D., Li H., van der Meide P.H., Ljunggren H.G., Link H. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin. Immunol. 2000, 95:156-162.
30. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 1997, 186:385-391.
31. Balasa B., Deng C., Lee J., Christadoss P., Sarvetnick N. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 1998, 161:2856-2862.
32. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
33. Aricha R., Feferman T., Fuchs S., Souroujon M.C. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J. Immunol. 2008, 180:2132-2139.
34. Chen Y., Akirav E.M., Chen W., Henegariu O., Moser B., Desai D., Shen J.M., Webster J.C., Andrews R.C., Mjalli A.M., Rothlein R., Schmidt A.M., Clynes R., Herold K.C. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 2008, 181:4272-4278.
35. Bernard M.P., Phipps R.P. CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production. Clin. Immunol. 2007, 125:138-148.